- Home
- BME vs VNDA Comparison
BME vs VNDA Comparison
Compare BME & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BME | VNDA |
|---|---|---|
| Founded | N/A | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 547.5M | 474.0M |
| IPO Year | 2005 | 2005 |
Fundamental Metrics
Financial Performance| Metric | BME | VNDA |
|---|---|---|
| Price | $42.20 | $8.60 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $14.13 |
| AVG Volume (30 Days) | 33.2K | ★ 3.3M |
| Earning Date | 01-01-0001 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $216,105,000.00 |
| Revenue This Year | N/A | $26.20 |
| Revenue Next Year | N/A | $31.02 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 8.72 |
| 52 Week Low | $34.18 | $3.81 |
| 52 Week High | $42.63 | $9.60 |
Technical Indicators
Market Signals| Indicator | BME | VNDA |
|---|---|---|
| Relative Strength Index (RSI) | 54.71 | 63.71 |
| Support Level | $41.21 | $4.25 |
| Resistance Level | $42.46 | $9.60 |
| Average True Range (ATR) | 0.45 | 0.48 |
| MACD | -0.01 | 0.19 |
| Stochastic Oscillator | 57.84 | 85.49 |
Price Performance
Historical ComparisonAbout BME Blackrock Health Sciences Trust
Blackrock Health Sciences Trust has an investment objective to provide total return through a combination of current income, current gains, and long-term capital appreciation. The Fund invests 80% of its total assets in equity securities of companies engaged in the health sciences and related industries and equity derivatives.
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.